This paper describes the development of a protein biological drug termed Link_TSG6 with disease modifying properties. Osteoarthritis (OA) is the most common form of joint disease, affecting more than ...

With an aggregate of $11 million raised in an initial Series A funding round, Doron Therapeutics is advancing its lead ...

biologic response modifiers (biologics) work by altering the function of the immune system that attacks the joints. These drugs must be administered by intravenous (by vein) infusion or by an ...

Osteoarthritis is a painful condition in which cartilage—the protective cushioning between the joints—gradually breaks down.

Dr Tsun Sean Law details the ARISE trials and outlines other orthobiologic treatments currently available — but not yet ...

Osteoarthritis (OA) is a condition that disproportionally affects postmenopausal women, and the millions affected can attest ...

“Scientists are already developing drugs which can act in this way for other conditions. Now, osteoarthritis can be part of this ... of this interesting and exciting study reveal a likely biological ...

Ampion is a biologic drug based on a blood-derived cyclised ... immune response characteristic of inflammatory disease. In osteoarthritis it is injected directly into the affect joint, in order ...

A new study led by researchers at the UNC Thurston Arthritis Research Center has made significant progress in this area. By ...

Osteoarthritis is a painful condition in which cartilage - the protective cushioning between the joints - gradually breaks ...

The purpose of this study was to investigate whether platelet-rich plasma therapy for early knee osteoarthritis is associated with good clinical outcomes and a change in magnetic resonance imaging ...

Osteoarthritis is a painful condition ... the team is currently conducting drug screening studies to find drug compounds that target the biological pathways of interest. "The hope is that we ...